Alzheimer's disease Dementia Neurodegenerative disorders
Conditions
Interventions
None listed
Sponsors
Takeda
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: MCI patients 1) Referred to the memory clinic for the evaluation of cognitive problems, and 2) Patients have to fulfil the new DSM-V criteria for mild neurocognitive disorder (NCD): a) Evidence of modest cognitive decline from a previous level of performance in one or more cognitive domains, being between 1-2 standard deviations (SD) below average. The evidence should consist of concern of the individual, a knowledgeable informant, or the clinician that there's been a mild decline in cognitive functioning; and a modest impairment in cognitive performance, documented by standardized neuropsychological testing. b) The cognitive deficits do not interfere with capacity for independence in everyday activities. c) The cognitive deficits don't occur exclusively in context of delirium, and are not better explained by another mental disorder. These inclusion criteria, and collection of clinical data, will allow use of different internationally used MCI criteria.;SCD patients (based on Jessen et al., Alz Dem, 2014) 1) Also being referred for the evaluation of cognitive complaints; 2) Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; and 3) Normal age-, gender-, and education- adjusted performance on standardized cognitive tests. SCD might be a very early symptom of neurodegenerative brain processes, and are therefore interesting for evaluation in the present study.
Exclusion criteria
Exclusion criteria: Exclusion criteria for both groups of patients are: having received chemo treatment in the past year, Normal Pressure Hydrocephalus, Morbus Huntington, Parkinson's Disease, recent Transient Ischemic Attack (TIA) or Cerebrovascular Accident (CVA) (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is memory decline on the Verbal Learning Test (VLT). Genetic markers will include DNA and RNA (expression). | — |
Secondary
| Measure | Time frame |
|---|---|
| The outcome of the other cognitive tests will be analysed as secondary outcome measures. | — |
Countries
Netherlands
Outcome results
None listed